German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT ID: NCT00199069
Last Updated: 2023-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
720 participants
INTERVENTIONAL
1993-04-30
2001-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199056
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00198991
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199004
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
NCT00199095
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
NCT00002531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Asparaginase
Vincristine
Daunorubicin, Adriamycin
Cyclophosphamide
Ifosfamide
Cytarabine
Mitoxantrone
Methotrexate
6-Mercaptopurine
6-Thioguanine
VM26
Dexamethasone / Prednisolone
CNS Irradiation
Mediastinal Irradiation
Stem Cell Transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 15 - 65 years
Exclusion Criteria
* Serious psychiatric diseases, which may compromise compliance with therapy
* HIV-1 or HIV-2 Infection
* Pretreatment \> 2 weeks or chemotherapy other than Vincristine and Steroids
* Patients without central diagnosis who cannot be allocated to a risk group
15 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Deutsche Krebshilfe e.V., Bonn (Germany)
OTHER
Goethe University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nicola Goekbuget
Study Coordinator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dieter Hoelzer, MD, PhD
Role: STUDY_CHAIR
University of Frankfurt, Medical Department II
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital, Medical Dept. II
Frankfurt, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
German Leukemia Trial Registry
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMALL09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.